Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer.
Chidley P, Foroudi F, Tacey M, Khor R, Yeh J, Bevington E, Hyett A, Loh SW, Chew G, McCracken J, Neoh D, Yeo B, Baker C, Jassal S, Law M, Zantuck N, Cokelek M, Guerrieri M, Brown B, Stoney D, Ng M, Chao M. Chidley P, et al. Among authors: brown b. J Med Imaging Radiat Oncol. 2021 Jun;65(3):345-353. doi: 10.1111/1754-9485.13180. Epub 2021 Apr 5. J Med Imaging Radiat Oncol. 2021. PMID: 33821576 Review.
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI); Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG). Chantrill LA, et al. Among authors: brown b. Clin Cancer Res. 2015 May 1;21(9):2029-37. doi: 10.1158/1078-0432.CCR-15-0426. Clin Cancer Res. 2015. PMID: 25896973 Clinical Trial.
Bispecific antibody targeting of lipid nanoparticles.
Amabile A, Phelan M, Yu Z, Silva P, Marks A, Morla-Folch J, Sohn M, Mollaoglu G, Falcomata C, Teunissen A, Brody J, Dong Y, Brown B. Amabile A, et al. Among authors: brown b. bioRxiv [Preprint]. 2024 Dec 22:2024.12.20.629467. doi: 10.1101/2024.12.20.629467. bioRxiv. 2024. PMID: 39763831 Free PMC article. Preprint.
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer.
Mattiuz R, Boumelha J, Hamon P, Le Berichel J, Vaidya A, Soong BY, Halasz L, Radkevich E, Kim HM, Park MD, Donne R, Troncoso L, D'Souza D, Kaiza ME, MacFawn IP, Belabed M, Mestrallet G, Humblin E, Merand R, Hennequin C, Ioannou G, Ozbey S, Figueiredo I, Hegde S, Tepper A, Merarda H, Nemeth E, Goldstein S, Reid AM, Noureddine M, Tabachnikova A, Ahmed J, Polydorides AD, Bhardwaj N, Lujambio A, Chen Z, Gonzalez Kozlova E, Kim-Schulze S, Brody JD, Schotsaert M, Moussion C, Gnjatic S, Sautès-Fridman C, Fridman WH, Roudko V, Brown BD, Marron TU, Cyster JG, Salmon H, Bruno TC, Joshi NS, Kamphorst AO, Merad M. Mattiuz R, et al. Among authors: brown bd. bioRxiv [Preprint]. 2024 Dec 27:2024.12.27.628014. doi: 10.1101/2024.12.27.628014. bioRxiv. 2024. PMID: 39763802 Free PMC article. Preprint.
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.
Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, Pandey A, Sfreddo H, Crowley F, Korostin MR, Debnath N, Leyfman Y, Valero C, Lee M, Vos JL, Lee AS, Zhao K, Lam S, Olumuyide E, Kuo F, Wilson EA, Hamon P, Hennequin C, Saffern M, Vuong L, Hakimi AA, Brown B, Merad M, Gnjatic S, Bhardwaj N, Galsky MD, Schadt EE, Samstein RM, Marron TU, Gönen M, Morris LGT, Chowell D. Yoo SK, et al. Among authors: brown b. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03398-5. Online ahead of print. Nat Med. 2025. PMID: 39762425
5,271 results